Justin Kim
Stock Analyst at Oppenheimer
(1.54)
# 3,514
Out of 5,124 analysts
38
Total ratings
40%
Success rate
-5.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Maintains: Outperform | $44 → $50 | $27.75 | +80.18% | 5 | Dec 4, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $17 → $16 | $5.24 | +205.34% | 2 | Aug 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $65 → $40 | $25.12 | +59.24% | 6 | Nov 6, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $107 → $106 | $63.54 | +66.82% | 5 | May 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $85 → $87 | $34.60 | +151.45% | 5 | Feb 29, 2024 | |
| VERA Vera Therapeutics | Initiates: Outperform | $26 | $50.64 | -48.66% | 1 | Jan 25, 2024 | |
| ALDX Aldeyra Therapeutics | Downgrades: Perform | n/a | $5.18 | - | 2 | Oct 17, 2023 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Perform | n/a | $15.95 | - | 6 | Nov 4, 2022 | |
| BCRX BioCryst Pharmaceuticals | Downgrades: Perform | n/a | $7.80 | - | 5 | Aug 8, 2022 | |
| IONS Ionis Pharmaceuticals | Assumes: Outperform | $59 | $79.11 | -25.42% | 1 | Jul 18, 2022 |
Pharvaris
Dec 4, 2025
Maintains: Outperform
Price Target: $44 → $50
Current: $27.75
Upside: +80.18%
Zura Bio
Aug 15, 2025
Maintains: Outperform
Price Target: $17 → $16
Current: $5.24
Upside: +205.34%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $65 → $40
Current: $25.12
Upside: +59.24%
Cytokinetics
May 9, 2024
Maintains: Outperform
Price Target: $107 → $106
Current: $63.54
Upside: +66.82%
Immunocore Holdings
Feb 29, 2024
Reiterates: Outperform
Price Target: $85 → $87
Current: $34.60
Upside: +151.45%
Vera Therapeutics
Jan 25, 2024
Initiates: Outperform
Price Target: $26
Current: $50.64
Upside: -48.66%
Aldeyra Therapeutics
Oct 17, 2023
Downgrades: Perform
Price Target: n/a
Current: $5.18
Upside: -
Aurinia Pharmaceuticals
Nov 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $15.95
Upside: -
BioCryst Pharmaceuticals
Aug 8, 2022
Downgrades: Perform
Price Target: n/a
Current: $7.80
Upside: -
Ionis Pharmaceuticals
Jul 18, 2022
Assumes: Outperform
Price Target: $59
Current: $79.11
Upside: -25.42%